Types of Diagnostics: Labs, Imaging, Point-of-Care, and Digital Health

Diagnostics is not a single market. It is a collection of distinct categories that share the goal of generating clinical information but differ in how they are built, cleared, sold, and paid for. A founder who treats laboratory diagnostics, imaging, point-of-care testing, and digital health tools as interchangeable will build the wrong regulatory strategy, target the wrong buyer, and price the product incorrectly for the channel it actually runs through.

Laboratory diagnostics — commonly called in vitro diagnostics, or IVDs — are tests performed on biological samples such as blood, urine, or tissue outside the human body. The dominant commercial form is a test run in a central laboratory, typically a hospital lab, a reference laboratory like Quest or LabCorp, or a specialty lab focused on a clinical area like oncology or infectious disease. Central labs invest heavily in automation, throughput, and assay panels, which means a new test entering this channel must justify its cost against existing workflows and deliver results that change clinical decisions or reduce downstream costs.

Imaging diagnostics generate clinical information through visual representation of anatomy or physiology. Modalities include X-ray, computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, and nuclear medicine approaches like PET scanning. Each modality has its own physics, its own capital cost structure, and its own clinical use cases — ultrasound is portable and low-cost; MRI is high-resolution but slow and expensive. The device in imaging is typically a capital purchase by a health system, while the clinical service is billed separately as a procedure. Founders entering imaging are almost always building software, hardware components, or AI-assisted reading tools layered on top of existing installed infrastructure.

Point-of-care testing, abbreviated POC, moves diagnostic testing to the location of patient care — a clinic, an emergency department, a pharmacy, a home. The defining characteristic is turnaround time: POC tests return results in minutes rather than hours or days. Speed changes clinical workflow, which is why POC commands a premium in many settings. The tradeoff is analytical sensitivity — POC tests are frequently less accurate than their central lab equivalents, and understanding where that tradeoff is acceptable versus dangerous is one of the most consequential clinical decisions a diagnostics founder makes.

Digital health diagnostics use software, sensors, or algorithms to generate clinical information without a physical assay or imaging modality. Continuous glucose monitors, wearable cardiac monitors, and AI-based screening tools that analyze retinal photographs are all examples. The regulatory boundary that matters here is Software as a Medical Device, or SaMD — a classification that the FDA has developed specific guidance around and that carries its own risk stratification logic. A digital health tool that generates a diagnosis or informs a treatment decision is regulated differently from one that provides general wellness information, and the line between those categories is less obvious than founders expect.

The buyer for each category is structurally different, and this shapes everything about go-to-market strategy. Central lab tests are evaluated by laboratory directors and medical directors who care about analytical performance, workflow integration, and total cost of testing. Imaging decisions are made by radiology departments and capital committee processes that move on multi-year procurement cycles. POC products are often purchased by nursing leadership or decentralized clinic operators who care about simplicity, CLIA waiver status, and training burden. Digital health tools increasingly require hospital IT security review, EHR integration, and clinical champion sponsorship before procurement. Knowing which buyer owns the decision changes who you hire to sell, what evidence they require, and how long your sales cycle will be.